(Reuters) – Amylyx Pharmaceuticals said on Thursday it would withdraw its amyotrophic lateral sclerosis (ALS) drug from the U.S. and Canada markets after the treatment failed in a crucial late-stage trial.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
Comments